Retrospective Evaluation of a Cohort of Patients Diagnosed With Pre- and Postnatal Urinary Dilatation: Outcome and Long-term Follow-up
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Jan 2, 2025
Trial Information
Current as of August 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at patients who were diagnosed with urinary tract dilatation either before or after birth. Urinary tract dilatation means that the tubes that carry urine from the kidneys to the bladder are wider than normal, which can sometimes lead to complications. The study aims to gather information about the outcomes and long-term follow-up for these patients to better understand how this condition affects them over time.
To be eligible for the trial, participants need to be children who were referred to specific medical centers between January 2000 and August 2021 for urinary tract dilatation. They must have had at least one ultrasound after birth that showed the condition, along with another follow-up ultrasound. It's important to note that the study is not accepting patients who have incomplete medical records or certain other kidney issues. Those who join the trial can expect their past medical information to be reviewed, helping researchers learn more about the condition and improve care for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Pediatric patients referred to one of the participating centers between January 1 2000 and August 31 2021 for either a prenatal or a postnatal diagnosis of urinary tract dilatation;
- • Urinary tract dilatation documented on at least one postnatal ultrasound, with related measurements;
- • Presence of at least one other ultrasound performed during follow-up in the postnatal period.
- Exclusion Criteria:
- • Lack of some of the clinical data considered crucial to the study, particularly incomplete ultrasound reports referable to at least two different ultrasounds performed in follow-up;
- • Dilatation with a picture of documented renal lithiasis.
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Patients applied
Trial Officials
Claudio La Scola, MD
Principal Investigator
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported